(S)-VQW-765
Product Specifications
UNSPSC Description
(S)-VQW-765 ((S)-AQW-051) is an orally active, selective and effective α7 nicotinic ACh receptor (nAChR) partial agonist. (S)-VQW-765 has potential applications in cognitive disorders related to neurological diseases, such as Alzheimer's disease or schizophrenia[1][2].
Target Antigen
nAChR
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel;Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/s-vqw-765.html
Purity
98.00
Solubility
10 mM in DMSO
Smiles
CC(C=C1)=CC=C1C2=NC=C(C=C2)O[C@H]3C4CCN(CC4)C3
Molecular Weight
294.39
References & Citations
[1]Feuerbach D, et al. AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation. Br J Pharmacol. 2015 Mar;172(5):1292-304. |[2]Mazurov A, et al. Nicotinic acetylcholine receptor modulators[J]. Small Molecule Therapeutics for Schizophrenia, 2015: 213-253.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-19490A/S-VQW-765-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-19490A/S-VQW-765-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
